Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Accounts Payables: 2022-2024

Historic Accounts Payables for Taysha Gene Therapies (TSHA) over the last 3 years, with Dec 2024 value amounting to $3.6 million.

  • Taysha Gene Therapies' Accounts Payables rose 10.26% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year increase of 10.26%. This contributed to the annual value of $3.6 million for FY2024, which is 43.58% down from last year.
  • As of FY2024, Taysha Gene Therapies' Accounts Payables stood at $3.6 million, which was down 43.58% from $6.4 million recorded in FY2023.
  • Over the past 5 years, Taysha Gene Therapies' Accounts Payables peaked at $10.9 million during FY2022, and registered a low of $3.6 million during FY2024.
  • Moreover, its 3-year median value for Accounts Payables was $6.4 million (2023), whereas its average is $7.0 million.
  • Data for Taysha Gene Therapies' Accounts Payables shows a maximum YoY slumped of 43.58% (in 2024) over the last 5 years.
  • Taysha Gene Therapies' Accounts Payables (Yearly) stood at $10.9 million in 2022, then plummeted by 41.84% to $6.4 million in 2023, then plummeted by 43.58% to $3.6 million in 2024.